Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma Co., Ltd. has announced its financial results for the first half of 2024, indicating a reduction in loss before tax to RMB 78.396 million compared to RMB 86.568 million during the same period last year. The report also shows a decrease in research and development expenses and a significant drop in current assets from the end of the previous year. Despite the reduction in losses, the company has not reported any income tax expense for the period.
For further insights into HK:2496 stock, check out TipRanks’ Stock Analysis page.